



University of HUDDERSFIELD

University of Huddersfield Repository

Ahmadi, M., Ahmadihosseini, Z., Allison, Simon J., Begum, S., Rockley, K., Sadiq, M., Chintamaneni, S., Lokwani, R., Hughes, N. and Phillips, R. M.

Hypoxia modulates the activity of a series of clinically approved tyrosine kinase inhibitors

Original Citation

Ahmadi, M., Ahmadihosseini, Z., Allison, Simon J., Begum, S., Rockley, K., Sadiq, M., Chintamaneni, S., Lokwani, R., Hughes, N. and Phillips, R. M. (2014) Hypoxia modulates the activity of a series of clinically approved tyrosine kinase inhibitors. *British Journal of Pharmacology*, 171 (1). pp. 224-236. ISSN 0007-1188

This version is available at <http://eprints.hud.ac.uk/id/eprint/23258/>

The University Repository is a digital collection of the research output of the University, available on Open Access. Copyright and Moral Rights for the items on this site are retained by the individual author and/or other copyright owners. Users may access full items free of charge; copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational or not-for-profit purposes without prior permission or charge, provided:

- The authors, title and full bibliographic details is credited in any copy;
- A hyperlink and/or URL is included for the original metadata page; and
- The content is not changed in any way.

For more information, including our policy and submission procedure, please contact the Repository Team at: E.mailbox@hud.ac.uk.

<http://eprints.hud.ac.uk/>

Hypoxia modulates the activity of a series of clinically approved tyrosine kinase inhibitors.

Running title: Hypoxia and tyrosine kinase inhibitor activity

M Ahmadi^{1*}, Z Ahmadihosseini^{1*}, S J Allison¹, S Begum¹, K Rockley¹, M Sadiq¹, S Chintamaneni¹, R Lokwani¹, N Hughes¹, and R M Phillips¹.

¹Institute of Cancer Therapeutics, University of Bradford, Bradford BD7 1DP, United Kingdom.

* These authors contributed equally to this work.

Author for correspondence: Roger M Phillips. Institute of Cancer Therapeutics, University of Bradford, Bradford BD7 1DP, United Kingdom. Tel: +44 1274 233226; Fax: +44 1274 233234; email: r.m.phillips@bradford.ac.uk

Summary

Background and purpose: Hypoxia in tumours is known to cause resistance to conventional chemotherapeutic drugs. In contrast, little is known about the effects of hypoxia on targeted anti-cancer drugs. This study evaluated the effect of hypoxia on a series of clinically approved tyrosine kinase inhibitors (TKIs). **Experimental approach:** The effect of hypoxia (0.1% oxygen) on the activity of conventional cytotoxic drugs (5-fluorouracil, doxorubicin and vinblastine), the hypoxia activated pro-drug tirapazamine and 9 TKIs was determined in a panel of cell lines. Where hypoxia had a marked effect on chemosensitivity, western blot analysis to determine the effect of hypoxia on target expression and the effect of TKIs on cell signalling response under aerobic and hypoxic conditions was conducted. **Key results:** Three patterns of chemosensitivity were observed; resistance under hypoxia, equi-toxic activity against hypoxic and aerobic cells and preferential cytotoxicity to hypoxic cells. Significant hypoxia selectivity (independent of HIF1) was observed in the case of dasatinib and this correlated with the ability of dasatinib to inhibit phosphorylation of Src at tyrosine 530. Sorafenib was significantly less effective under hypoxic conditions but resistance did not correlate with hypoxia induced changes in RAF/MEK/ERK signalling. **Conclusions and implications:** Hypoxia influences the activity of TKIs but in contrast to conventional cytotoxic drugs, preferential activity against hypoxic cells can occur. The search for hypoxia targeted therapies has been long and fruitless and this study suggests that some clinically approved TKIs could preferentially target the hypoxic fraction of some tumour types.

Keywords: hypoxia, tyrosine kinase inhibitors, Src, dasatinib, sorafenib, HIF1.

Introduction

One of the characteristic features of solid tumours is the development of a microenvironment caused by a poor and inefficient vascular supply (Vaupel *et al.*, 2013). This physiological microenvironment is characterised by gradients of oxygen tension, nutrients, catabolites, cellular metabolites, cell proliferation and extracellular pH, all of which vary as a function of distance from a supporting blood vessel (Brown, 2002; Vaupel, 2010). The presence of hypoxia has significant biological and therapeutic implications and hypoxia is established as a marker of poor prognosis in many cancer types (Vaupel, 2008). Resistance to conventional cytotoxic anti-cancer drugs has been extensively studied and whilst it is widely acknowledged that resistance is caused by hypoxia induced reduction in cell proliferation, other mechanisms are emerging (Brown, 2002; Rohwer *et al.*, 2011; Brahimi-Horn *et al.*, 2012; Flamant *et al.*, 2012; Onishi *et al.*, 2012; Wu *et al.*, 2012). In addition, the fact that hypoxic cells reside some distance away from blood vessels introduces drug delivery challenges and this further compounds the resistance of this population of cells (Heldin *et al.*, 2004; Minchinton *et al.*, 2006). The need to develop therapeutic approaches that target the hypoxic fraction was recognised many years ago and seminal studies by Sartorelli's group showing that mitomycin C can target hypoxic cells (Kennedy *et al.*, 1980; Sartorelli *et al.*, 1994) led to the search for more effective hypoxia selective drugs. Hypoxia activated bioreductive prodrugs were actively pursued for many years and a number entered clinical trial (Wilson *et al.*, 2011). Whilst elegant in concept, this approach has however proved extremely difficult to translate into clinical efficacy. Novel compounds are still being developed (McKeage *et al.*, 2011; Weiss *et al.*, 2011; Sun *et al.*, 2012) and are in clinical trial but the fact remains that after 40 years of research and development, no hypoxia selective

bio-reductive drugs have been approved for use in humans. The need to develop hypoxia selective drugs is even more prominent today as our understanding of the impact that hypoxia has on tumour biology and therapy increases.

In contrast to conventional cytotoxic drugs, little or no information has been published concerning the effects of hypoxia on targeted therapeutics. Hypoxia is known to induce a plethora of biochemical changes, many of which are mediated by hypoxia inducible factors (Rohwer *et al.*, 2011), and signal transduction pathways are influenced by hypoxia. This is exemplified by studies demonstrating that the expression of Src and phosphorylated Src proteins is elevated in hypoxic regions of pancreatic and cervical carcinoma xenografts (Pham *et al.*, 2009). Furthermore, studies using the Bcl-2 inhibitor ABT-737 clearly demonstrate that targeted therapeutics can selectively kill hypoxic cells (Harrison *et al.*, 2011; Klymenko *et al.*, 2011). The hypoxia selective activity of ABT-737 was attributed to hypoxia induced down regulation of myeloid cell leukaemia sequence-1, a protein that causes resistance to ABT-737 (Harrison *et al.*, 2011). These studies demonstrate that hypoxia can modulate the activity of targeted anticancer drugs. The identification of clinically used tyrosine kinase inhibitors (TKIs) that are selectively toxic to hypoxic cells would be beneficial and would stimulate the design of novel combination strategies with drugs that preferentially target the aerobic fraction. In addition, resistance of hypoxic cells to TKIs would significantly influence the outcome of chemotherapy and this knowledge could help tailor chemotherapy to individuals who are most likely to benefit from these drugs. Given the importance of TKIs and other small molecule drugs in treating cancer, it is important to characterise the effects of hypoxia on the activity of targeted anti-cancer drugs (Filippi *et al.*, 2011). The aim of this study was

to determine whether the response of a panel of cell lines to TKIs was influenced by hypoxia. Where differences between cellular response under aerobic and hypoxic conditions was obtained, additional studies were conducted to identify mechanisms of action.

Materials and methods

All standard cytotoxic drugs (Doxorubicin, vinblastine and 5-Fluorouracil), tirapazamine and tyrosine kinase inhibitors were prepared in DMSO, aliquoted and stored at -20°C until required for use. All cell culture reagents were obtained from Sigma Aldrich unless stated otherwise.

Cell lines and culture conditions.

As little is known about the effects of hypoxia on TKIs, the experimental design involved the evaluation of a number of TKIs against a panel of human cancer cell lines. As the TKIs evaluated had multiple mechanisms of action, it was not feasible to select cell lines that harboured specific mutations or activated pathways. In the initial phase of the project therefore, the cell lines used were DLD-1 human colorectal carcinoma, H460 and A549 human NSCLC cells, MDA-MB-231 human breast cancer and TK10 human renal cancer cells. An extended panel of cell lines was used to study the effects of hypoxia on the activity of dasatinib and these consisted of MDA-MB-468, MDA-MB-453, Hs578T, BT-20, T47D and MCF7, all of which are derived from human breast carcinomas. A549, H460, MDA-MB-231, MDA-MB-453, MCF7 and TK10 cells were obtained from the National Cancer Institute (Bethesda, USA). DLD-1, Hs578T, BT20, T47D and MDA-MB-468 cells were purchased from the American Type Culture Collection (LGC Standards, London, UK).

Chemosensitivity studies

Chemosensitivity under aerobic and hypoxic conditions was determined using the MTT assay as described previously (Phillips *et al.*, 1992). Studies under hypoxia were performed in a Whitley H35 Hypoxystation (Don Whitley Scientific, UK). In this study, hypoxia was defined as 0.1% oxygen which is a physiologically relevant level of hypoxia that is associated with resistance to radiotherapy, the induction of HIF1 activation and unfolded protein response (Wilson *et al.*, 2011). It is also important to stress that these conditions are distinct from the majority of studies on bioreductive prodrugs where conditions of anoxia are typically used to evaluate compounds (Wilson *et al.*, 2011). Initial validation of the MTT assay demonstrated that a linear relationship between cell number and absorbance was obtained under both hypoxic and aerobic conditions. Following a 24 hour exposure to 0.1% oxygen, linear regression analysis of the relationship between cell number and absorbance were identical to those obtained under aerobic conditions with the exception of A549 cells where r values of 4.97×10^5 and 2.02×10^5 were obtained under aerobic and hypoxic conditions respectively (data not shown). Even though the efficiency of MTT conversion to formazan was reduced in A549 cells under hypoxia, the relationship between cell number and absorbance is linear. To further confirm the suitability of the MTT assay for use under hypoxic conditions, cellular response was also determined by counting viable cells using a haemocytometer following continuous exposure to dasatinib.

For chemosensitivity studies, cells were plated into 96 well plates at a density of 2×10^3 cells per well and incubated under aerobic or hypoxic conditions (0.1% oxygen) at

37°C in a CO₂ enriched atmosphere overnight to allow cells to attach. The following day, media was removed from each well and replaced with media containing test compounds at a range of concentrations (8 wells per drug concentration). For hypoxia studies, drugs were diluted in media that had been conditioned under hypoxia for at least 24 hours prior to the start of the experiment. Following a 5 day incubation at 37°C in a CO₂ enriched atmosphere, MTT (0.5mg/ml) was immediately added to each well and incubated for 4 hours. Formazan crystals were dissolved in DMSO and the absorbance of the resulting solution was measured at 570nm. Cell survival was determined as the true absorbance of the treated wells divided by the controls and expressed as a percentage. The effect of hypoxia on the activity of drugs was expressed as the hypoxic cytotoxicity ratio (HCR), which is defined as the ratio of IC₅₀ values under aerobic to hypoxic conditions.

Antibodies and Western blot analysis.

Antibodies to Src and p-Src (Src antibody sampler kit), EGFR and p-EGFR signalling pathways (Phosph-EGFR antibody sampler kit), Raf signalling (Raf family antibody sampler kit) and phospho ERK1/2 signalling (phosphor-ERK1/2 pathway sampler kit) were obtained from Cell Signalling Technology[®] (Beverly, MA). Antibodies to β -actin were obtained from Santa Cruz Biotechnology (USA). Secondary antibodies were horseradish peroxidase linked anti-mouse, or anti-rabbit. To determine the effect of selected tyrosine kinase inhibitors on cell signalling, cells were conditioned to hypoxia (0.1% oxygen) and normoxia for 24 hours prior to drug exposure. Cells were exposed to a range of drug concentrations for a further 24 hours prior to cell lysis and analysis by Western blotting. Images of immunoblots were digitally captured on

Molecular Imager FX and individual bands were quantified using Quantity One software (Biorad, Hemel Hempsted, UK).

Role of HIF1 in the hypoxia selective activity of dasatinib.

HIF1 α protein expression was determined by Western blot analysis following the incubation of MDA-MB-231, MDA-MB-468 and MCF7 cells in 0.1% oxygen for 24 hours. Western blot analysis was performed using a purified mouse anti-HIF1 α antibody obtained from BD Biosciences (Oxford, UK) and band intensities from three independent experiments were quantified using Quantity One software (Biorad, Hemel Hempsted, UK). Under aerobic conditions, MDA-MB-231, MDA-MB-468 and MCF7 cells were exposed to CoCl₂ for 6 hours (150 μ M) or 24 hours (100 μ M) and HIF α expression determined as above. Once HIF1 α expression had been confirmed, cells were exposed to dasatinib for one hour in the presence or absence of CoCl₂ and cell survival determined using the MTT assay following a 5 day recovery period at 37°C.

Quantitation of apoptosis following exposure of cells to dasatinib under aerobic and hypoxic conditions.

MCF7, MDA-MB-468 and MDA-MB-231 cells were exposed to a range of dasatinib concentrations under aerobic and hypoxic conditions for 24 hours. Cells were harvested by trypsinisation and the percentage of cells undergoing apoptosis was determined by flow cytometry following Annexin-V-FLUOS staining (Roche, Penzberg, Germany) as described previously (Allison *et al.*, 2009).

Results.

Chemosensitivity studies.

The response of cell lines to standard classical anti-cancer drugs (doxorubicin, 5-FU and vinblastine) and the hypoxia selective agent tirapazamine are presented in table 1 and HCR values are presented graphically in figure 1. The classical anti-cancer drugs tested were generally more active against cells under aerobic conditions compared to hypoxic (0.1% oxygen) conditions with some exceptions. In the case of doxorubicin, activity against MDA-MB-231 cells was similar under aerobic and hypoxic conditions ($IC_{50} = 0.42 \pm 0.01$ and 0.46 ± 0.05 μ M respectively) and TK10 cells were marginally more responsive under hypoxic conditions ($IC_{50} = 0.34 \pm 0.03$ and 0.26 ± 0.05 μ M respectively). H460 cells were also equally sensitive to vinblastine under aerobic and hypoxic conditions ($IC_{50} = 1.23 \pm 0.03$ and 1.36 ± 0.10 μ M respectively). The magnitude of the effect of hypoxia on the cellular response to each drug was cell line dependent (figure 1). The hypoxia selective agent tirapazamine was preferentially active against all cell lines under hypoxic conditions although HCR values varied across the panel of cell lines (2.71 to 9.63 in MDA-MB-231 and A549 cells respectively, figure 1). Exposure to 0.1% oxygen induced a partial G1 arrest in the majority of cell lines within 24 to 48 hours (data not shown). These results are consistent with reduced cell growth observed under hypoxia (data not shown) and resistance to the conventional cytotoxic drugs evaluated in this study.

The response of cell lines to TKIs under hypoxic and aerobic conditions is reported in table 1 and HCR values are presented in figure 2. Three patterns of response were observed: resistance under hypoxia ($HCR < 1$), equi-potent activity under aerobic and hypoxic conditions ($HCR \approx 1$) and sensitivity under hypoxia ($HCR > 1$). With the

exception of sorafenib, which was more resistant under hypoxia and imatinib which was equally active under aerobic and hypoxic conditions against all 5 cell lines, considerable heterogeneity in HCR values to individual drugs exist across the panel of cell lines tested (table 1, figure 2). This is illustrated most prominently in the case of dasatinib. Comparing the response of cells to dasatinib under aerobic and hypoxic conditions, A549 cells are resistant to dasatinib under hypoxic conditions (HCR = 0.007) whereas MDA-MB-231 cells were significantly ($p < 0.01$) more sensitive under hypoxia compared to oxygenated cells (HCR = 5.50). Haemocytometer counts of control and dasatinib treated MDA-MB-231 cells gave a HCR of 6.49 providing further verification that the MTT assay is appropriate for use under these experimental conditions. Other examples where all three patterns of response exist include erlotinib, sunitinib, nilotinib, and masatinib (figure 2). In contrast to the conventional drugs tested, gefitinib, vandetinib and imatinib generally have equi-potent activity under hypoxic and aerobic conditions (table 1, figure 2).

As dasatinib induced a significant increase in response under hypoxia in the MDA-MB-231 breast cancer cell line and c-Src is a potential target in breast cancer (Tryfonopoulos *et al.*, 2011), the effect of dasatinib against an extended panel of breast cancer cell lines was determined. The results are presented in table 2. As in the MDA-MB-231 cell line, dasatinib was significantly ($p < 0.01$) more potent under hypoxia against MDA-MB-468 and MCF7 cell lines with HCR values of 5.23 and 15.00 respectively. The response of MDA-MB-453 and Hs578T cells were similar under aerobic and hypoxic conditions with HCR values of 1.38 and 0.91 respectively. In contrast, T47D and BT20 cells were significantly ($p < 0.01$) more resistant under hypoxic conditions with HCR values of 0.62 and 0.12 respectively (table 2). Whereas

basal levels of apoptosis in MDA-MB-468 cells were similar under aerobic and hypoxic conditions, dasatinib induced significantly ($P < 0.01$) more apoptosis across a range of doses in hypoxic cells (figure 3). This would account for the increased potency of dasatinib observed under hypoxia. Similar results were obtained for MDA-MB-231 and MCF7 cells (data not shown).

Based on the results, three compounds were selected for further studies designed to explore the mechanistic basis for hypoxia sensitivity or resistance. These were dasatinib, erlotinib and sorafenib.

Influence of hypoxia on the expression of Src.

The effect of 24 hour exposure to 0.1% oxygen on Src and p-Src levels in the panel of cell lines tested is presented in figure 4A. Under normoxic conditions, Src protein expression ranged from high (A549 and H460) to comparatively low (DLD-1, MDA-MB-231 and TK10). Exposure to hypoxia increased levels of Src expression in DLD-1, MDA MB 231, A549 and TK10 but had little effect of Src levels in H460 cells. Levels of pSrcY419 were influenced by exposure to hypoxia with increased expression observed in all cell lines except H460 cells (figure 4A). Expression of pSrcY530 decreased under hypoxia in all cells with the exception of DLD-1 cells where hypoxia had no obvious effect on pSrcY530 expression (figure 4A).

Influence of dasatinib on Src signalling under aerobic and hypoxic conditions.

The effect of dasatinib on Src and pSrc expression has been determined in hypoxia sensitive and resistant cells taken from both the initial panel of cell lines evaluated (figure 4B) and the extended panel of breast cancer lines (figure 5). In the initial panel

of cell lines, the effect of hypoxia on Src and p-Src expression 24 hours after treatment with a range of dasatinib concentrations in A549 (hypoxia resistant) and MDA-MB-231 (hypoxia sensitive) cells is presented in figure 4B. Under aerobic conditions, expression of pSrcY419 is reduced by dasatinib at doses as low as 5 nM (figure 4B). There was no significant difference in the inhibition of pSrcY419 under hypoxia and aerobic conditions in either cell line (figure 4B). A similar pattern of response was observed in the breast cancer panel of cells with no major differences in the ability of dasatinib to inhibit pSrcY419 expression under aerobic and hypoxic conditions (figure 5).

In contrast, differences in the ability of dasatinib to inhibit the expression of pSrcY530 between aerobic and hypoxic cells were observed. In the hypoxia resistant A549 cells, pSrcY530 was effectively inhibited by dasatinib under aerobic conditions but not under hypoxic conditions (figure 4B). In the hypoxia sensitive MDA-MB-231 cells, pSrcY530 expression was preferentially inhibited by dasatinib under hypoxic conditions (figure 4B). A similar pattern of response was observed in the extended panel breast cancer cell lines but the differential effects of dasatinib on pSrc530 expression were less extreme (figure 5). These results suggest that the effects of dasatinib on pSrcY530 expression have a greater impact on cell response under hypoxic conditions than dephosphorylation of pSrcY419.

Role of HIF1 in the hypoxia selective activity of dasatinib.

The role of HIF1 in the hypoxic potentiation of dasatinib activity was determined in MCF7, MDA-MB-231 and MDA-MB-468 cells (figure 6). HIF1 α expression was undetectable in all three cell lines under aerobic conditions. Following a 24 hour

exposure to 0.1% oxygen, a prominent increase in HIF1 α levels was observed in the MCF7 and MDA-MB-468 cell lines whereas only a very minor increase in HIF1 α was observed in MDA-MB-231 cells (figure 6A). Under aerobic conditions, treatment of cells with either 150 μ M or 100 μ M CoCl₂ for 6 or 24 hours respectively induced HIF1 α in all three cell lines (figure 6A). As treatment of cells with 150 μ M CoCl₂ for 6 hours induced HIF1 α expression significantly in all cell lines, these conditions were used to determine the effect of HIF1 α on cellular response to dasatinib. As illustrated in figure 6B, the response of cell lines to dasatinib in the presence of CoCl₂ was reduced (MCF7) or equivalent (MDA-MB-231 and MDA-MB-468) to the response of cells treated with dasatinib alone. These results together with the very modest induction of HIF1 α under hypoxic conditions in the MDA-MB-231 cells, suggests that the hypoxia selective activity of dasatinib is independent of HIF1.

Influence of hypoxia and exposure to erlotinib on EGFR expression.

Under aerobic conditions, EGFR protein expression was highest in TK10, MDA-MB-231 and A549 cells (figure 7A). Under hypoxic conditions, there was a significant increase in EGFR levels in A549, DLD-1 and H460 whereas hypoxia had little effect in MDA-MB-231 and TK10 cells (figure 7A). The expression of phosphorylated EGFR (pEGFR Y1068) shows marked differences under hypoxia. In TK10 cells, p-EGFR is strongly expressed under both aerobic and hypoxic conditions whereas in DLD-1 and A549 cells, there was a significant increase in p-EGFR under hypoxic conditions (figure 7A). No differences in the expression of pEGFR occurred between aerobic and hypoxic conditions in MDA-MB-231 cells and pEGFR was barely detectable in H460 cells under both aerobic and hypoxic conditions (figure 7A).

The effect of erlotinib on EGFR and pEGFR levels in TK10 (hypoxia resistant) and DLD-1 (marginally hypoxia sensitive) is presented in figure 7B. In the hypoxia resistant TK10 cell line, treatment with erlotinib for 24 hours did not affect the levels of EGFR but caused a dose dependent reduction in levels of pEGFR under both hypoxic and aerobic conditions (figure 7B). Under aerobic conditions levels of pEGFR were undetectable in cells treated with 60µM erlotinib whereas under hypoxic conditions, pEGFR was still detectable at 100µM (figure 7B). In DLD1 cells where the effects of hypoxia on the activity of erlotinib were marginally in favour of hypoxia selectivity (HCR = 1.36), no significant differences were observed in the ability of erlotinib to inhibit pEGFR were observed, despite the increased expression of EGFR under hypoxia (figure 7B).

Relationship between cellular response to sorafenib and inhibition of RAF/MEK/ERK signalling pathways.

Chemosensitivity studies demonstrated that sorafenib was the only drug that was less effective under hypoxic conditions across the panel of cell lines evaluated. HCR values ranged from 0.40 to 0.027 in DLD-1 and TK10 cells respectively (figure 2). The influence of hypoxia on the expression of RAF/MEK/ERK signalling pathways is presented in figure 8. Exposure to 0.1% oxygen for 24 hours affects the expression of p-cRaf, p-MEK1,2, p44/42 MAPK and p90RSK in a cell line dependent manner (figure 8) but these changes do not correlate with the emergence of resistance to sorafenib under hypoxia.

Discussion

The resistance of hypoxic cells to the classical cytotoxic anti-cancer drugs has broadly been attributed to hypoxia induced changes in the cell cycle but more recent studies have demonstrated that other mechanisms exist (Brahimi-Horn *et al.*, 2012; Flamant *et al.*, 2012; Onishi *et al.*, 2012; Wu *et al.*, 2012). With the exception of doxorubicin that can be equally or more effective against certain cell types under hypoxic conditions (Teicher *et al.*, 1981; Luk *et al.*, 1990), the majority of cell lines used were resistant to classical cytotoxic drugs under hypoxic conditions (figure 1, table1). In contrast, the response of cells to TKIs under aerobic and hypoxic conditions varied in a cell line dependent manner with three main patterns of response observed (table1, figure 2). These were resistance under hypoxia, equitoxic effects under aerobic and hypoxic conditions and sensitivity under hypoxia. With the exception of sorafenib (which was resistant under hypoxia in all cell lines tested) and imatinib (which was equally active against hypoxic and aerobic cells), cellular response under hypoxia was strongly cell line dependent with all three patterns of response observed in many cases (figure 2). Responses to dasatinib for example ranged from hypoxia resistance in the case of A549 cells (HCR = 0.007) to hypoxia sensitivity in MDA-MB-231, MDA-MB-468 and MCF7 cells (HCR = 5.50, 5.23 and 15.00 respectively, figure 2, table 2). Increased sensitivity to dasatinib under hypoxia was with increased cell kill as opposed to reduced cell growth, with a significant increase in apoptosis observed in MDA-MB-468, MDA-MB-231 and MCF7 (figure 3 and data not shown) cell lines.

Dasatinib is an orally active inhibitor of Abl and Src kinases (Lombardo *et al.*, 2004) and in broad agreement with previous studies (Pham *et al.*, 2009), an increase in total Src expression was observed under hypoxic conditions in all cell lines with the

exception of H460 cells (figure 4A). Human c-Src signalling output is controlled post-translationally by phosphorylation at Y530 and Y419 (Yeatman, 2004).

Phosphorylation at Y530 inactivates c-Src whereas full activation requires phosphorylation at Y419. Under hypoxic conditions, cell line dependent changes in the expression of both pSrcY419 and pSrcY530 occurred (figure 4A) but no clear relationship between c-Src and p-Src and hypoxia resistance or sensitivity exists (figures 4 and 5). The ability of dasatinib treatment to dephosphorylate pSrcY530 did however correlate with cellular response and in the hypoxia sensitive cell lines, greater dephosphorylation of the inhibitory pSrcY530 occurred (figures 4B and 5) making cells more sensitive to dasatinib. In the hypoxia resistant cell lines, the dephosphorylation of pSrcY530 was reduced under hypoxia conditions (figures 4B and 5) thereby keeping c-Src in an inactive state. The ability of dasatinib to dephosphorylate pSrcY530 (rather than pSrcY419) contributes significantly to the differential response of cells to dasatinib. Further studies to determine the effect of dasatinib on Csk and Chk proteins that inactivate Src by phosphorylation at Y530 and the activating Src activator protein tyrosine phosphatase 1B (PTP1B) (Yeatman, 2004; Roskoski, 2005) are required. Hypoxic sensitisation of cells to dasatinib appears to be independent of HIF1 (figure 6). This is consistent with other studies showing that forced expression of HIF1 repressed Src signalling output by repressing transcription of PTP1B thereby conferring resistance to dasatinib (Suwaki *et al.*, 2011). As cobalt chloride is known to stabilise HIF2 α in aerobic conditions (Chan *et al.*, 2002), our results (figure 6) also suggest that HIF2 is not involved in the hypoxic sensitisation of cells to dasatinib. Another potential mechanism that may influence response in normoxia and hypoxia is higher drug efflux capacity in hypoxic stem cell populations

(Challen *et al.*, 2006). Further studies are required to verify these and other potential mechanisms of resistance.

The impact of hypoxia on EGFR signalling pathways is of current interest (Wouters *et al.*, 2013) and resistance to gefitinib under hypoxia has been reported in NSCLC cell lines that harbour both mutant and wild type EGFR (Minakata *et al.*, 2012). The results of our study are broadly in agreement in that resistance to erlotinib and gefitinib was observed in some cell lines although HCR values close to 1 was seen in others (table 1, figure 2). The effect of hypoxia on the expression of EGFR and pEGFR varied depending on the cell line (figure 7A) with increased expression seen in some cells (eg DLD1) contrasting with no significant change in other cells (eg TK10). Increased expression of EGFR under hypoxia has been reported previously (Wang *et al.*, 2010; Misra *et al.*, 2012) but it is not clear why induction is cell line dependent. A trend between the ability of erlotinib to suppress p-EGFR and response under aerobic and hypoxic conditions exists. In hypoxia resistant TK10 cells, reduced dephosphorylation of EGFR was observed under hypoxic conditions whereas little difference in the suppression of p-EGFR expression was observed in DLD-1 cells where erlotinib was equally active against aerobic and hypoxic cells (figure 7B). Our results further support the view that tumour hypoxia is an important factor that should be considered when treating patients (Minakata *et al.*, 2012). Further work is required to identify the mechanisms responsible for the cell dependent nature of the hypoxia response to EGFR inhibitors.

Sorafenib inhibits RAF/MEK/ERK signalling (Liu *et al.*, 2006) but no obvious correlation was observed between resistance under hypoxia and the expression of

proteins involved in RAF/MEK/ERK signalling (figure 8). Sorafenib is however a multi-kinase inhibitor (Matsuda *et al.*, 2011) and further studies are required to determine the role of RAF/MEK/ERK independent pathways in conferring hypoxia resistance. The resistance of cells under hypoxia is however potentially significant as sorafenib, by virtue of its anti-angiogenic properties, has been shown to induce hypoxia in renal cell carcinoma xenografts (Murakami *et al.*, 2012). Recent studies have demonstrated that the development of a resistance to sorafenib is not due to permanent genetic changes or selection of resistant clones but is due to reversible changes that occur within the tumour or its microenvironment (Tang *et al.*, 2010; Zhang *et al.*, 2011). It is conceivable that the induction of hypoxia by sorafenib could generate a resistance phenotype, an effect that would be transient in nature depending upon oxygenation levels. Alternative dosing strategies including low dose metronomic (Tang *et al.*, 2010) and high dose intermittent dosing (Wang *et al.*, 2011) have shown improved efficacy in preclinical models but it is not clear whether this improved efficacy is due to reducing the induction of tumour hypoxia.

In conclusion, the results of this study demonstrate that cell lines exposed to normoxic and hypoxic conditions can induce differential responses to clinically used TKIs. This includes preferential toxicity towards hypoxic cells as exemplified by dasatinib. In the context of the failure to develop therapies that selectively target hypoxic cells (Semenza, 2012), this study suggests that TKIs that show preferential toxicity towards hypoxic cells should be evaluated as potential hypoxia selective therapies. In the case of dasatinib, the activity of single agent dasatinib against solid tumours in the clinic has so far proved disappointing (Zhang *et al.*, 2012), but further evaluation of dasatinib as a hypoxia selective drug could be valuable. In this context, combination

strategies using agents that target the aerobic fraction of tumours would be required and various preclinical studies have provided evidence that this is an attractive strategy (Montero *et al.*, 2011; Raju *et al.*, 2012). Whilst translating the results of this in vitro study into in vivo efficacy against hypoxic cells is challenging, this study suggests that certain TKIs should be re-evaluated as potential hypoxia selective therapies designed to overcome hypoxia induced drug resistance.

Acknowledgements: The authors would like to acknowledge partial financial support from Yorkshire Cancer Research (pump priming grant BPP028).

References.

- Allison SJ, Jiang M, Milner J (2009). Oncogenic viral protein HPV E7 up-regulates the SIRT1 longevity protein in human cervical cancer cells. *Aging* **1**(3): 316-327.
- Brahimi-Horn MC, Ben-Hail D, Ilie M, Gounon P, Rouleau M, Hofman V, *et al.* (2012). Expression of a truncated active form of VDAC1 in lung cancer associates with hypoxic cell survival and correlates with progression to chemotherapy resistance. *Cancer research* **72**(8): 2140-2150.
- Brown JM (2002). Tumor microenvironment and the response to anticancer therapy. *Cancer biology & therapy* **1**(5): 453-458.
- Challen GA, Little MH (2006). A side order of stem cells: the SP phenotype. *Stem cells* **24**(1): 3-12.
- Chan DA, Sutphin PD, Denko NC, Giaccia AJ (2002). Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha. *The Journal of biological chemistry* **277**(42): 40112-40117.
- Filippi I, Naldini A, Carraro F (2011). Role of the hypoxic microenvironment in the antitumor activity of tyrosine kinase inhibitors. *Current medicinal chemistry* **18**(19): 2885-2892.
- Flamant L, Roegiers E, Pierre M, Hayez A, Sterpin C, De Backer O, *et al.* (2012). TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells. *BMC cancer* **12**: 391.
- Harrison LR, Micha D, Brandenburg M, Simpson KL, Morrow CJ, Denneny O, *et al.* (2011). Hypoxic human cancer cells are sensitized to BH-3 mimetic-induced apoptosis via downregulation of the Bcl-2 protein Mcl-1. *The Journal of clinical investigation* **121**(3): 1075-1087.
- Heldin CH, Rubin K, Pietras K, Ostman A (2004). High interstitial fluid pressure - an obstacle in cancer therapy. *Nature reviews. Cancer* **4**(10): 806-813.

- Kennedy KA, Rockwell S, Sartorelli AC (1980). Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells. *Cancer research* **40**(7): 2356-2360.
- Klymenko T, Brandenburg M, Morrow C, Dive C, Makin G (2011). The novel Bcl-2 inhibitor ABT-737 is more effective in hypoxia and is able to reverse hypoxia-induced drug resistance in neuroblastoma cells. *Molecular cancer therapeutics* **10**(12): 2373-2383.
- Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, *et al.* (2006). Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. *Cancer research* **66**(24): 11851-11858.
- Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, *et al.* (2004). Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. *Journal of medicinal chemistry* **47**(27): 6658-6661.
- Luk CK, Veinot-Drebot L, Tjan E, Tannock IF (1990). Effect of transient hypoxia on sensitivity to doxorubicin in human and murine cell lines. *Journal of the National Cancer Institute* **82**(8): 684-692.
- Matsuda Y, Fukumoto M (2011). Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. *Medical molecular morphology* **44**(4): 183-189.
- McKeage MJ, Gu Y, Wilson WR, Hill A, Amies K, Melink TJ, *et al.* (2011). A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients. *BMC cancer* **11**: 432.
- Minakata K, Takahashi F, Nara T, Hashimoto M, Tajima K, Murakami A, *et al.* (2012). Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors. *Cancer science* **103**(11): 1946-1954.
- Minchinton AI, Tannock IF (2006). Drug penetration in solid tumours. *Nature reviews. Cancer* **6**(8): 583-592.
- Misra A, Pandey C, Sze SK, Thanabalu T (2012). Hypoxia activated EGFR signaling induces epithelial to mesenchymal transition (EMT). *PloS one* **7**(11): e49766.
- Montero JC, Seoane S, Ocana A, Pandiella A (2011). Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research* **17**(17): 5546-5552.
- Murakami M, Zhao S, Zhao Y, Chowdhury NF, Yu W, Nishijima K, *et al.* (2012). Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma. *International journal of oncology* **41**(5): 1593-1600.
- Onishi H, Morifuji Y, Kai M, Suyama K, Iwasaki H, Katano M (2012). Hedgehog inhibitor decreases chemosensitivity to 5-fluorouracil and gemcitabine under hypoxic conditions in pancreatic cancer. *Cancer science* **103**(7): 1272-1279.
- Pham NA, Magalhaes JM, Do T, Schwock J, Dhani N, Cao PJ, *et al.* (2009). Activation of Src and Src-associated signaling pathways in relation to hypoxia in human cancer xenograft models. *International journal of cancer. Journal international du cancer* **124**(2): 280-286.
- Phillips RM, Hulbert PB, Bibby MC, Sleight NR, Double JA (1992). In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicity. *British journal of cancer* **65**(3): 359-364.

- Raju U, Riesterer O, Wang ZQ, Molkentine DP, Molkentine JM, Johnson FM, *et al.* (2012). Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways. *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology* **105**(2): 241-249.
- Rohwer N, Cramer T (2011). Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. *Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy* **14**(3): 191-201.
- Roskoski R, Jr. (2005). Src kinase regulation by phosphorylation and dephosphorylation. *Biochemical and biophysical research communications* **331**(1): 1-14.
- Sartorelli AC, Hodnick WF, Belcourt MF, Tomasz M, Haffty B, Fischer JJ, *et al.* (1994). Mitomycin C: a prototype bioreductive agent. *Oncology research* **6**(10-11): 501-508.
- Semenza GL (2012). Molecular mechanisms mediating metastasis of hypoxic breast cancer cells. *Trends in molecular medicine* **18**(9): 534-543.
- Sun JD, Liu Q, Wang J, Ahluwalia D, Ferraro D, Wang Y, *et al.* (2012). Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research* **18**(3): 758-770.
- Suwaki N, Vanhecke E, Atkins KM, Graf M, Swabey K, Huang P, *et al.* (2011). A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. *Science translational medicine* **3**(85): 85ra47.
- Tang TC, Man S, Xu P, Francia G, Hashimoto K, Emmenegger U, *et al.* (2010). Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. *Neoplasia* **12**(11): 928-940.
- Teicher BA, Lazo JS, Sartorelli AC (1981). Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. *Cancer research* **41**(1): 73-81.
- Tryfonopoulos D, Walsh S, Collins DM, Flanagan L, Quinn C, Corkery B, *et al.* (2011). Src: a potential target for the treatment of triple-negative breast cancer. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* **22**(10): 2234-2240.
- Vaupel P (2008). Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. *The oncologist* **13 Suppl 3**: 21-26.
- Vaupel P (2010). Metabolic microenvironment of tumor cells: a key factor in malignant progression. *Experimental oncology* **32**(3): 125-127.
- Vaupel P, Kelleher DK (2013). Blood flow and oxygenation status of prostate cancers. *Advances in experimental medicine and biology* **765**: 299-305.
- Wang X, Schneider A (2010). HIF-2alpha-mediated activation of the epidermal growth factor receptor potentiates head and neck cancer cell migration in response to hypoxia. *Carcinogenesis* **31**(7): 1202-1210.
- Wang X, Zhang L, Goldberg SN, Bhasin M, Brown V, Alsop DC, *et al.* (2011). High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma. *Journal of translational medicine* **9**: 220.
- Weiss GJ, Infante JR, Chiorean EG, Borad MJ, Bendell JC, Molina JR, *et al.* (2011). Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. *Clinical cancer research : an official journal of the American Association for Cancer Research* **17**(9): 2997-3004.

Wilson WR, Hay MP (2011). Targeting hypoxia in cancer therapy. *Nature reviews. Cancer* **11**(6): 393-410.

Wouters A, Boeckx C, Vermorken JB, Van den Weyngaert D, Peeters M, Lardon F (2013). The Intriguing Interplay Between Therapies Targeting the Epidermal Growth Factor Receptor, the Hypoxic Microenvironment and Hypoxia-inducible Factors. *Current pharmaceutical design* **19**(5): 907-917.

Wu YC, Ling TY, Lu SH, Kuo HC, Ho HN, Yeh SD, *et al.* (2012). Chemotherapeutic sensitivity of testicular germ cell tumors under hypoxic conditions is negatively regulated by SENP1-controlled sumoylation of OCT4. *Cancer research* **72**(19): 4963-4973.

Yeatman TJ (2004). A renaissance for SRC. *Nature reviews. Cancer* **4**(6): 470-480.

Zhang L, Bhasin M, Schor-Bardach R, Wang X, Collins MP, Panka D, *et al.* (2011). Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. *PloS one* **6**(4): e19144.

Zhang S, Yu D (2012). Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. *Trends in pharmacological sciences* **33**(3): 122-128.

Table 1. Response of a panel of cell lines to conventional cytotoxic drugs, tirapazamine and targeted therapeutics under normoxic (N) and hypoxic (H) conditions. Cells were pre-incubated under normal and hypoxic (0.1% oxygen) conditions for 24 hours prior to a 96 hour exposure to each drug. Cell survival was determined using the MTT assay and results are expressed as IC₅₀ values. The units are μ M in all cases with the exception of those marked by an asterix where the units are nM. Each value represents the mean \pm standard deviation of three independent experiments. Statistical analysis comparing response under hypoxia to aerobic conditions was performed using the students t-test and p values of < 0.05 and 0.01 are represented as $^+$ and $^{++}$ respectively.

Drug	A549	H460	MDA MB231	DLD1	TK10
5FU (N)	2.28 \pm 0.56	1.97 \pm 1.27	14.61 \pm 9.23	3.03 \pm 0.59	41.35 \pm 7.92
5FU (H)	15.13 \pm 3.72 ⁺⁺	6.54 \pm 1.13 ⁺⁺	39.17 \pm 5.21 ⁺⁺	12.62 \pm 3.02 ⁺⁺	72.99 \pm 25.38 ⁺
Dox (N)	0.25 \pm 0.04	0.023 \pm 0.006	0.42 \pm 0.01	0.074 \pm 0.004	0.34 \pm 0.03
Dox (H)	1.00 \pm 0.14 ⁺⁺	0.066 \pm 0.011 ⁺	0.46 \pm 0.05	0.43 \pm 0.05 ⁺⁺	0.26 \pm 0.05
Vinblastine (N)	0.72 \pm 0.05	1.23 \pm 0.03	0.55 \pm 0.06	2.47 \pm 0.79	2.40 \pm 0.17
Vinblastine (H)	2.13 \pm 0.69 ⁺⁺	1.36 \pm 0.10	0.85 \pm 0.10	5.28 \pm 0.44 ⁺	7.43 \pm 1.43 ⁺⁺
Tirapazamine(N)	23.13 \pm 3.41	22.85 \pm 1.12	7.84 \pm 0.86	15.91 \pm 1.23	19.69 \pm 2.54
Tirapazamine(H)	2.40 \pm 1.34 ⁺⁺	2.53 \pm 0.92 ⁺⁺	2.89 \pm 0.65 ⁺⁺	2.95 \pm 1.68 ⁺⁺	3.38 \pm 1.15 ⁺⁺
Sunitinib (N)	4.82 \pm 0.31	3.73 \pm 2.00	8.17 \pm 1.13	2.85 \pm 0.73	8.02 \pm 0.63
Sunitinib (H)	4.97 \pm 0.42	2.54 \pm 0.47	5.08 \pm 0.49	0.50 \pm 0.09 ⁺⁺	5.92 \pm 0.62
Sorafenib (N)	2.74 \pm 1.50	1.42 \pm 0.13	0.51 \pm 0.34	1.16 \pm 0.53	0.25 \pm 0.05
Sorafenib (H)	21.63 \pm 6.12 ⁺⁺	5.49 \pm 0.95 ⁺⁺	2.10 \pm 1.38 ⁺⁺	2.90 \pm 0.77 ⁺	9.02 \pm 3.05 ⁺⁺
Gefitinib (N)	23.32 \pm 3.62	14.90 \pm 1.11	10.62 \pm 0.82	10.46 \pm 1.94	0.97 \pm 0.27
Gefitinib (H)	16.69 \pm 2.41	22.34 \pm 2.12 ⁺⁺	11.85 \pm 0.78	7.22 \pm 1.81 ⁺	9.10 \pm 3.50 ⁺⁺
Masatinib (N)	18.17 \pm 0.51	12.47 \pm 1.52	8.39 \pm 2.02	16.33 \pm 3.10	14.72 \pm 3.65
Masatinib (H)	18.75 \pm 2.81	18.47 \pm 1.04 ⁺⁺	12.93 \pm 2.23 ⁺	5.34 \pm 0.61 ⁺⁺	10.40 \pm 0.78
Vandetinib (N)	7.60 \pm 3.77	8.75 \pm 0.78	8.12 \pm 0.99	6.68 \pm 1.90	2.35 \pm 1.92
Vandetinib (H)	8.07 \pm 0.84	10.54 \pm 0.37	5.56 \pm 2.56 ⁺	4.25 \pm 0.53 ⁺	1.82 \pm 0.39
Dasatinib (N)	0.17 \pm 0.01	14.52 \pm 1.48	33.0 \pm 9.53*	2.25 \pm 0.04	3.62 \pm 1.08*
Dasatinib (H)	23.92 \pm 8.58 ⁺⁺	11.18 \pm 1.27	6.0 \pm 4.35* ⁺⁺	25.09 \pm 4.43 ⁺⁺	12.17 \pm 2.55* ⁺⁺
Nilotinib (N)	7.61 \pm 0.86	5.86 \pm 1.89	2.81 \pm 1.00	8.08 \pm 2.64	1.12 \pm 0.68
Nilotinib (H)	9.98 \pm 1.66	9.04 \pm 0.94 ⁺	1.73 \pm 1.02	5.39 \pm 0.42	24.53 \pm 0.99 ⁺⁺
Imatinib (N)	32.77 \pm 0.85	23.76 \pm 2.15	18.28 \pm 0.68	21.58 \pm 1.68	15.90 \pm 3.17
Imatinib (H)	33.28 \pm 3.85	22.89 \pm 3.10	19.69 \pm 1.30	17.54 \pm 1.20	18.96 \pm 1.71
Erlotinib (N)	3.74 \pm 0.67	11.58 \pm 0.85	15.70 \pm 0.36	10.33 \pm 0.65	4.71 \pm 2.12
Erlotinib (H)	33.83 \pm 3.23 ⁺⁺	29.58 \pm 10.99 ⁺⁺	20.11 \pm 0.54 ⁺	7.56 \pm 0.81 ⁺	47.25 \pm 8.41 ⁺⁺

Table 2. Response of a panel of breast carcinoma cell lines exposed to dasatinib under aerobic and hypoxic conditions for 96 hours. Each value represents the mean \pm standard deviation for at least three independent experiments. Statistical analysis comparing response under hypoxia to aerobic conditions was performed using the students t-test and p values of < 0.05 and 0.01 are represented as $^+$ and $^{++}$ respectively.

Cell line	Aerobic IC ₅₀ (μ M)	Hypoxic IC ₅₀ (μ M)	HCR
MCF7	0.18 \pm 0.11	0.012 \pm 0.007 $^{++}$	15.00
MDA-MB-231	0.033 \pm 0.009	0.006 \pm 0.004 $^{++}$	5.50
MDA-MB-468	16.58 \pm 2.47	3.17 \pm 1.70 $^{++}$	5.23
MDA-MB-453	8.27 \pm 3.36	5.97 \pm 1.45	1.38
Hs578T	0.044 \pm 0.016	0.048 \pm 0.013	0.91
T47D	10.45 \pm 2.98	16.85 \pm 2.53 $^+$	0.62
BT20	1.14 \pm 0.59	9.63 \pm 4.06 $^{++}$	0.12

Legends to figures

Figure 1. Hypoxic Cytotoxicity Ratios (HCR) for 5-Fluorouracil, Doxorubicin, Vinblastine and Tirapazamine. The centre line represents a HCR of 1, which indicates that the response of cells under aerobic and hypoxia is equal. A HCR value greater than one indicates sensitivity under hypoxia. HCR of less than one indicates resistance under hypoxia. Each HCR is calculated from mean IC_{50} values obtained from three independent experiments (table 1). Experimental error in the form of standard deviations for IC_{50} values is presented in table 1.




Figure 2. Influence of hypoxia (0.1% oxygen) on the response of a panel of human cancer cells lines to tyrosine kinase inhibitors. Each HCR is calculated from mean IC_{50} values obtained from three independent experiments (table 1). Experimental error for IC_{50} values is presented in table 1.




Figure 3. Induction of cell death following the treatment of MDA-MB-468 cells with dasatinib. Cells were exposed to dasatinib under aerobic and hypoxic (0.1% oxygen) for 24 hours prior to analysis of early apoptotic cells (annexin V positive cells) and cells undergoing late apoptosis/necrosis (annexin V and propidium iodide [PI] positive cells). Each value represents the mean \pm standard deviation for three independent experiments.




Figure 4. Influence of hypoxia and dasatinib on Src and p-Src levels. The influence of a 24 hour exposure to 0.1% oxygen on the levels of Src, pSrcY419 and pSrcY530 in 5 cell lines is presented in panel A. In panel A, 231 refers to the MDA-MB-231 cell line. The effect of dasatinib (in aerobic and hypoxic conditions) on Src, pSrcY419 and pSrcY530 in the hypoxia sensitive MDA-MB-231 and hypoxia resistant A549 cells is presented in panel B. In both cases, cells were exposed to dasatinib for 24 hours prior to harvesting for immunoblotting. Graphs show the quantification (\pm standard deviation) of Src (open bars), pSrc Y419 (solid bars) and pSrc Y530 (hatched bars) after normalisation to β -actin for a minimum of n = 3 experiments.




Figure 5. Influence of hypoxia and dasatinib on Src and pSrc expression in a hypoxia sensitive and resistant breast cancer cell lines. Western blot analysis of Src, pSrcY419 and pSrcY530 following the treatment of hypoxia sensitive (MDA-MB-468 and MCF7) and resistant (BT20) cells with dasatinib for 24 hours under aerobic and hypoxic conditions. Graphs show the quantification (\pm standard deviation) of Src (open bars), pSrcY419 (solid bars) and pSrcY530 (hatched bars) after normalisation to β -actin for a minimum of $n = 3$ experiments.




Figure 6. The role of HIF1 in the activity of dasatinib. Western blot analysis of the effect of hypoxia (24 hour exposure to 0.1% oxygen) and CoCl₂ (6 hour exposure to 150 μ M and 24 hour exposure to 100 μ M CoCl₂ under aerobic conditions) on the expression of HIF1 α is presented in panel A. The values presented below each lane represent the ratio of HIF1 α to β -actin expression as determined by densitometry. The response of cells to dasatinib in the absence and presence of CoCl₂ is presented in panel B. Cells were pre-treated with 150 μ M CoCl₂ for 6 hours prior to a one hour exposure to dasatinib and 150 μ M CoCl₂. Each value presented represents the mean \pm standard deviation for three independent experiments. Statistical significance (P<0.01) between the control (no CoCl₂) and CoCl₂ treated groups is indicated by *.




Figure 7. Influence of hypoxia and erlotinib treatment on the expression of EGFR and pEGFR. The expression of EGFR and pEGFR (Y1068) under aerobic conditions and following 24 hours exposure to 0.1% oxygen is presented in panel A. The expression of EGFR and pEGFR in TK10 (hypoxia resistant, HCR=0.09) and DLD-1 cells (hypoxia sensitive, HCR=1.36) following 24 hours exposure to erlotinib (1 to 100 μ M) under aerobic and hypoxic conditions is presented in panel B. Graphs show the quantification (\pm standard deviation) of EGFR and p-EGFR after normalisation to β -actin for a minimum of n = 3 experiments.





Figure 8. Influence of hypoxia on Raf/Mek/Erk signalling. The expression of proteins involved in Raf/Mek/Erk signalling in 5 cell lines was determined following a 24 hour exposure to either aerobic or hypoxic (0.1% oxygen). The lane labelled MDA refers to the cell line MDA-MB-231. The values quoted directly under each blot represent quantitation of band intensities after normalisation to β -actin. The values presented represent the mean of 3 independent experiments but error bars have been omitted in the interests of clarity of presentation.



Statement of conflicts of interest: None.